Cortisol Specific Neutra™ Antibody Products

Are prolonged timelines in stress-related drug development or inconsistent cortisol detection hindering your progress? Creative Biolabs' cortisol-specific Neutra™ antibody products overcome these challenges using advanced epitope mapping and high-affinity hybridoma technology, empowering you to accelerate therapeutic discovery and enhance assay reproducibility.

Introduction to Cortisol

Cortisol, a glucocorticoid hormone synthesized in the adrenal cortex, serves as a central regulator of metabolic, immune, and stress responses. Its production follows a circadian rhythm, peaking in the early morning and declining throughout the day. Cortisol exerts widespread effects via binding to glucocorticoid receptors (GRs), influencing gene expression and cellular signaling across tissues. Dysregulation of cortisol secretion or signaling underpins numerous pathologies, making it a critical therapeutic and diagnostic target.

• Structural Insights

Cortisol (C₂₁H₃₀O₅) shares a steroidal backbone with cholesterol-derived hormones. Its structure includes a tetracyclic core with hydroxyl groups at positions 11β, 17α, and 21, essential for receptor binding and bioactivity. Unlike synthetic glucocorticoids, cortisol lacks fluorine substitutions, rendering its activity dependent on endogenous regulatory pathways.

• Associated Signaling Pathways

Cortisol activates cytoplasmic GRs, which translocate to the nucleus to modulate transcription of target genes. Key pathways include:

- Anti-inflammatory signaling: GRs suppress pro-inflammatory cytokines (e.g., TNF-α, IL-6) by blocking NF-κB and AP-1 activity.

- Metabolic regulation: Cortisol enhances gluconeogenesis via PEPCK activation and antagonizes insulin signaling.

- Stress adaptation: It primes the hypothalamic-pituitary-adrenal (HPA) axis, amplifying responses to chronic stressors.

Fig.1 Τhe process of cortisol signaling via the glucocorticoid receptor (GCR/GR).¹

• Linked Pathologies

Cortisol dysregulation is implicated in Cushing's syndrome (hypercortisolism), characterized by central obesity and hypertension, and Addison's disease (hypocortisolism), marked by fatigue and hypoglycemia. Chronic elevation contributes to metabolic syndrome, depression, and immunosuppression, while deficiency exacerbates autoimmune disorders and inflammation.

Applications of Cortisol-Specific Neutralizing Antibodies

• Therapeutic Intervention in Hypercortisolism

Neutralizing antibodies reduce circulating bioactive cortisol, offering a targeted approach for Cushing's syndrome. By preventing GR activation, they mitigate insulin resistance and cardiovascular risks without systemic glucocorticoid depletion.

• Diagnostic Tool Development

High-specificity antibodies enable ultrasensitive cortisol detection in saliva, hair, or serum, aiding in circadian rhythm analysis and stress biomarker studies. These tools improve diagnostic accuracy for adrenal disorders and psychiatric conditions linked to HPA axis dysfunction.

• Preclinical Stress Models

In rodent models, anti-cortisol antibodies attenuate chronic stress-induced behaviors (e.g., anxiety) and physiological markers (e.g., elevated blood glucose), validating their utility in neuroendocrine research.

Anti-Cortisol Antibodies

Creative Biolabs' cortisol-specific antibodies are engineered to bind cortisol with sub-nanomolar affinity, neutralizing its bioactivity by sterically blocking GR interactions. Applications include:

- Quantifying free cortisol: Eliminate interference from corticosteroid-binding globulin (CBG) in serum/plasma assays.

- Functional studies: Investigate cortisol's role in GR-dependent gene regulation using competitive ELISA or Western blot.

- Therapeutic development: Screen cortisol-neutralizing candidates for treating Cushing's syndrome or stress-induced comorbidities.

Creative Biolabs provides cortisol-specific Neutra™ antibody portfolio that combines rigorous validation, exceptional batch consistency, and customizable formats (ELISA, IHC, flow cytometry) to advance your projects.

Contact our team today to explore tailored solutions for your cortisol-related research or therapeutic development.

REFERENCE

1. Ilias, Ioannis, et al. "Changes in cortisol secretion and corticosteroid receptors in COVID-19 and non COVID-19 Critically Ill patients with sepsis/septic shock and scope for treatment." Biomedicines 11.7 (2023): 1801. Distributed under Open Access license CC BY 3.0, without modification. https://doi.org/10.3390/biomedicines11071801